**3. Results**

The mean serum levels of sRAGE were significantly lower in patients with warts compared to healthy controls (1036.50 ± 207.60 pg/mL vs. 1215.32 ± 266.12 pg/mL, *p* < 0.05) (Table 1). Differences were also obtained for TAS levels (1.85 ± 0.12 vs. 2.03 ± 0.14 μmol Trolox Eq/L, *p* < 0.05), TOS levels (3.17 ± 0.27 vs. 2.93 ± 0.22 μmol H2O2 Eq/L, *p* < 0.01) and OSI (1.72 ± 0.22 vs. 1.45 ± 0.17, *p* < 0.01) compared to controls, (Table 1). The determination of the markers of inflammation did not reveal a relevant inflammatory process in patients with warts. The only exception was represented by hs-CRP levels. The mean level of hs-CRP was 0.19 ± 0.14 mg/dL in patients with warts and 0.06 ± 0.02 mg/dL in controls (*p* < 0.05). In contrast, IL-6, fibrinogen, and ESR did not show significant differences between the two groups (Table 1).


**Table 1.** The serum levels of sRAGE, oxidative stress parameters and markers of inflammation in patients with warts versus controls (expressed as mean and standard deviation).

> *n* = number of the patients. \*—statistically significant.

The serum levels of the studied parameters did not differ significantly according to the number of the lesions between the groups (Table 2).

**Table 2.** The serum levels of sRAGE, oxidative stress parameters and markers of inflammation in patients with warts (expressed as mean and standard deviation) according to the number of the lesions.


The patients were divided into three groups; *n* = number of the patients.

There were no significantly differences between groups when we stratified patients according to the duration of the disease (Table 3).

**Table 3.** The serum levels of sRAGE, oxidative stress parameters and markers of inflammation in patients with warts (expressed as mean and standard deviation) according to the duration of the disease (months).


The patients were divided into three groups; *n* = number of the patients.

In patients with warts, sRAGE levels showed a positive statistically significant association with TAS (rho = 0.43, *p* < 0.05) and a negative statistically significant association with both TOS (rho = −0.90, *p* < 0.01) and OSI (rho = −0.86, *p* < 0.01) (Table 3). There was a lack of correlation between the levels of sRAGE and hs-CRP, IL-6, fibrinogen, and ESR in patients with warts (Table 4).


**Table 4.** The relationship between sRAGE and the markers of oxidative stress and inflammation, in patients with warts.

\*—statistically significant.
